2019

Loyola, L. et al. (2019) Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model. PLoS Pathogens, 15(12), e1008154. (doi: 10.1371/journal.ppat.1008154) (PMID:31815961) (PMCID:PMC6974304)

2018

Anderson, G. et al. (2018) RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins. Journal of Cellular Biochemistry, 119(3), pp. 2750-2762. (doi: 10.1002/jcb.26443) (PMID:29052866) (PMCID:PMC5813226)

McCarroll, C. S. et al. (2018) Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. Circulation, 137(1), pp. 57-70. (doi: 10.1161/CIRCULATIONAHA.117.028911) (PMID:29030345) (PMCID:PMC5757664)

2016

Borland, G. et al. (2016) Addiction to Runx1 is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model. Oncotarget, 7(17), pp. 22973-22987. (doi: 10.18632/oncotarget.8554) (PMID:27056890) (PMCID:PMC5029604)

2015

Naseer, A. et al. (2015) Frequent infection of human cancer xenografts with murine endogenous retroviruses in vivo. Viruses, 7(4), pp. 2014-2029. (doi: 10.3390/v7042014) (PMID:25912714) (PMCID:PMC4411688)

2014

McDonald, L. et al. (2014) RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Disease Models and Mechanisms, 7(5), pp. 525-534. (doi: 10.1242/dmm.015040)

Huser, C. A. et al. (2014) Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis. PLoS Genetics, 10(2), e1004167. (doi: 10.1371/journal.pgen.1004167) (PMID:24586197) (PMCID:PMC3937229)

2009

Blyth, K. , Slater, N., Hanlon, L., Bell, M., Mackay, N., Stewart, M., Neil, J.C. and Cameron, E.R. (2009) Runx1 promotes B-cell survival and lymphoma development. Blood Cells, Molecules, and Diseases, 43(1), pp. 12-19. (doi: 10.1016/j.bcmd.2009.01.013)

Scobie, L. et al. (2009) A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Molecular Therapy, 17(6), pp. 1031-1038. (doi: 10.1038/mt.2009.59)

2007

Kilbey, A., Blyth, K. , Wotton, S., Terry, A., Jenkins, A., Bell, M., Hanlon, L., Cameron, E.R. and Neil, J.C. (2007) Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Research, 67(23), pp. 11263-11271. (doi: 10.1158/0008-5472.CAN-07-3016)

2006

Blyth, K. , Vaillant, F., Hanlon, L., Mackay, N., Bell, M., Jenkins, A., Neil, J.C. and Cameron, E.R. (2006) Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Research, 66(4), pp. 2195-2201. (doi: 10.1158/0008-5472.CAN-05-3558) (PMID:16489021)

2001

Blyth, K. , Terry, A., Mackay, N., Vaillant, F., Bell, M., Cameron, E.R. , Neil, J.C. and Stewart, M. (2001) Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene, 20(3), pp. 295-302. (doi: 10.1038/sj.onc.1204090) (PMID:11313958)

2000

Blyth, K. , Stewart, M., Bell, M., James, C., Evan, G., Neil, J. C. and Cameron, E. R. (2000) Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycERTM mice. Oncogene, 19(6), pp. 773-782. (doi: 10.1038/sj.onc.1203321) (PMID:10698495)

1999

Vaillant, F., Blyth, K. , Terry, A., Bell, M., Cameron, E. R. , Neil, J. and Stewart, M. (1999) A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene, 18(50), pp. 7124-7134. (doi: 10.1038/sj.onc.1203202) (PMID:10597314)

Articles

Loyola, L. et al. (2019) Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model. PLoS Pathogens, 15(12), e1008154. (doi: 10.1371/journal.ppat.1008154) (PMID:31815961) (PMCID:PMC6974304)

Anderson, G. et al. (2018) RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins. Journal of Cellular Biochemistry, 119(3), pp. 2750-2762. (doi: 10.1002/jcb.26443) (PMID:29052866) (PMCID:PMC5813226)

McCarroll, C. S. et al. (2018) Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. Circulation, 137(1), pp. 57-70. (doi: 10.1161/CIRCULATIONAHA.117.028911) (PMID:29030345) (PMCID:PMC5757664)

Borland, G. et al. (2016) Addiction to Runx1 is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model. Oncotarget, 7(17), pp. 22973-22987. (doi: 10.18632/oncotarget.8554) (PMID:27056890) (PMCID:PMC5029604)

Naseer, A. et al. (2015) Frequent infection of human cancer xenografts with murine endogenous retroviruses in vivo. Viruses, 7(4), pp. 2014-2029. (doi: 10.3390/v7042014) (PMID:25912714) (PMCID:PMC4411688)

McDonald, L. et al. (2014) RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Disease Models and Mechanisms, 7(5), pp. 525-534. (doi: 10.1242/dmm.015040)

Huser, C. A. et al. (2014) Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis. PLoS Genetics, 10(2), e1004167. (doi: 10.1371/journal.pgen.1004167) (PMID:24586197) (PMCID:PMC3937229)

Blyth, K. , Slater, N., Hanlon, L., Bell, M., Mackay, N., Stewart, M., Neil, J.C. and Cameron, E.R. (2009) Runx1 promotes B-cell survival and lymphoma development. Blood Cells, Molecules, and Diseases, 43(1), pp. 12-19. (doi: 10.1016/j.bcmd.2009.01.013)

Scobie, L. et al. (2009) A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Molecular Therapy, 17(6), pp. 1031-1038. (doi: 10.1038/mt.2009.59)

Kilbey, A., Blyth, K. , Wotton, S., Terry, A., Jenkins, A., Bell, M., Hanlon, L., Cameron, E.R. and Neil, J.C. (2007) Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Research, 67(23), pp. 11263-11271. (doi: 10.1158/0008-5472.CAN-07-3016)

Blyth, K. , Vaillant, F., Hanlon, L., Mackay, N., Bell, M., Jenkins, A., Neil, J.C. and Cameron, E.R. (2006) Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Research, 66(4), pp. 2195-2201. (doi: 10.1158/0008-5472.CAN-05-3558) (PMID:16489021)

Blyth, K. , Terry, A., Mackay, N., Vaillant, F., Bell, M., Cameron, E.R. , Neil, J.C. and Stewart, M. (2001) Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene, 20(3), pp. 295-302. (doi: 10.1038/sj.onc.1204090) (PMID:11313958)

Blyth, K. , Stewart, M., Bell, M., James, C., Evan, G., Neil, J. C. and Cameron, E. R. (2000) Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycERTM mice. Oncogene, 19(6), pp. 773-782. (doi: 10.1038/sj.onc.1203321) (PMID:10698495)

Vaillant, F., Blyth, K. , Terry, A., Bell, M., Cameron, E. R. , Neil, J. and Stewart, M. (1999) A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene, 18(50), pp. 7124-7134. (doi: 10.1038/sj.onc.1203202) (PMID:10597314)